Big Pharma Sharma

Big Pharma Sharma

Share this post

Big Pharma Sharma
Big Pharma Sharma
ASCO/EHA/ICML 2023 Look-back: CAR-T Remains King in DLBCL and MM

ASCO/EHA/ICML 2023 Look-back: CAR-T Remains King in DLBCL and MM

Impressive data from Yescarta and Carvykti set both CAR-T therapies up to extend leadership in DLBCL and MM, respectively

Big Pharma Sharma's avatar
Big Pharma Sharma
Jul 05, 2023
∙ Paid
2

Share this post

Big Pharma Sharma
Big Pharma Sharma
ASCO/EHA/ICML 2023 Look-back: CAR-T Remains King in DLBCL and MM
Share

Executive Summary

Multiple CAR-T data sets were presented at the summer oncology conference series, confirming the long-term potential of CAR-T as a primary treatment modality in heme malignancies. P3 data from Yescarta (axi-cel; GILD) and Carvykti (cilta-cel; JNJ, LEGN) in earlier lines of therapy in DLBCL and MM, respectively, demonstrated major improvements in survival endpoints and will help cement CAR-T as SoC in these settings and GILD, JNJ/LEGN as market leaders in their particular spaces. GILD’s CD19 CAR-T franchise appears poised to usurp Roche’s CD20 mAb franchise in NHL, while JNJ continues to be well positioned to become the market leader in MM, pushing aside BMS.

Keep reading with a 7-day free trial

Subscribe to Big Pharma Sharma to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Big Pharma Sharma LLC
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share